Senti Biosciences (SNTI) on Thursday filed a registration statement for the potential offering of about 52.9 million common shares by certain selling securityholders.
The company said it would not receive any proceeds from the potential sale. However, it added that it received around $47.6 million in proceeds from the issuances of the series A preferred stock and will receive proceeds from the exercise of the warrants, if exercised for cash.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.